Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Coronary Artery Aneurysm

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    25 result(s) found for: Coronary Artery Aneurysm. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2009-016823-74 Sponsor Protocol Number: CDZ-PE-002 Start Date*: 2010-01-27
    Sponsor Name:Cardoz AB
    Full Title: An open pilot study to assess the effects of pemirolast on C-reactive protein levels in subjects with coronary artery disease.
    Medical condition: Cardoz AB intends to develope pemirolast as an anti-inflammatory agent. The first intended indication for the product under development is abdominal aortic aneurysm. The proposed clinical study...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10000054 Abdominal aortic aneurysm LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-000192-14 Sponsor Protocol Number: TMC-CAN-05-02 Start Date*: 2006-12-21
    Sponsor Name:The Medicines Company
    Full Title: A Clinical Trial Comparing Cangrelor To Clopidogrel In Subjects Who Require Percutaneous Coronary Intervention
    Medical condition: Subjects with coronary atherosclerosis who require PCI (with or without stent).
    Disease: Version SOC Term Classification Code Term Level
    8.1 10011093 Coronary atherosclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) ES (Completed) DE (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-004208-37 Sponsor Protocol Number: 20120153 Start Date*: 2013-04-23
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Multi-Center, Placebo-Controlled, Parallel Group Study to Determine the Effects of AMG-145 Treatment on Atherosclerotic Disease Burden As Measured By Intravascular Ultrasound in Patie...
    Medical condition: Coronary Artery Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004849 10011079 Coronary artery disease NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) NL (Completed) BE (Completed) SE (Completed) CZ (Completed) HU (Completed) ES (Completed) DE (Completed) GR (Completed) FI (Prematurely Ended) NO (Completed) IE (Completed) DK (Prematurely Ended) IS (Completed)
    Trial results: View results
    EudraCT Number: 2019-004433-17 Sponsor Protocol Number: 124210 Start Date*: 2020-02-18
    Sponsor Name:MRC CTU at UCL
    Full Title: Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary arte...
    Medical condition: Kawasaki Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10047065 - Vascular disorders 10023320 Kawasaki's disease PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Ongoing) EE (Ongoing) SE (Ongoing) FI (Ongoing) ES (Ongoing) DE (Ongoing) NL (Ongoing) IT (Ongoing) AT (Ongoing) CZ (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-000620-28 Sponsor Protocol Number: LPS14245 Start Date*: 2015-07-06
    Sponsor Name:sanofi-aventis groupe
    Full Title: A Multi-Country, Multicenter, Single-Arm, Open-Label Study to Document the Safety, Tolerability and Effect of Alirocumab on atherogenic lipoproteins in High Cardio-Vascular Risk Patients With Sever...
    Medical condition: Hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    19.0 10027433 - Metabolism and nutrition disorders 10020603 Hypercholesterolaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) CZ (Completed) SK (Completed) BE (Completed) IT (Completed) HU (Completed) AT (Completed) DE (Completed) FR (Completed) SE (Completed) ES (Completed) FI (Completed) PL (Completed) GR (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2016-003485-11 Sponsor Protocol Number: 1002-043 Start Date*: 2017-02-16
    Sponsor Name:Esperion Therapeutics Inc.,
    Full Title: A Randomized, Double-blind, Placebo-controlled Study to Assess the Effects of Bempedoic Acid (ETC-1002) on the Occurrence of Major Cardiovascular Events in Patients with, or at high risk for, Cardi...
    Medical condition: Patients with, or at high risk for, cardiovascular disease (CVD) who are statin intolerant.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10007541 - Cardiac disorders 10007648 Cardiovascular disease, unspecified LLT
    20.0 10007541 - Cardiac disorders 10007649 Cardiovascular disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) NL (Completed) LV (Completed) LT (Completed) GB (GB - no longer in EU/EEA) DK (Completed) DE (Completed) HU (Completed) BG (Completed) CZ (Completed) PL (Completed) ES (Completed) HR (Completed) BE (Completed) AT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2008-006968-11 Sponsor Protocol Number: AP214-CS005 Start Date*: 2009-04-21
    Sponsor Name:Action Pharma A/S
    Full Title: Pharmacokinectics of AP214 Acetate in patients undergoing cardiac surgery. A randomized, double-blind, placebo-controlled sequential ascending dose trial investigating pharmacokinetics, as well as...
    Medical condition: Action Pharma A/S is developing AP214 Acetate for the prevention of postsurgical kidney injury after thoracic aortic aneurysm repair surgery. In phase 2: Patients undergoing cardiac surgery, defin...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10056675 Postoperative renal failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001069-28 Sponsor Protocol Number: D5881C00004 Start Date*: 2015-02-10
    Sponsor Name:AstraZeneca AB
    Full Title: A Long-Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia (STRENGTH)
    Medical condition: Severe persistent Hypertriglyceridemia in High Cardiovascular Risk Patients
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10020870 Hypertriglyceridemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) GB (Prematurely Ended) EE (Completed) LT (Prematurely Ended) HU (Prematurely Ended) IT (Prematurely Ended) DK (Prematurely Ended) NL (Prematurely Ended) PL (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-003590-24 Sponsor Protocol Number: LPL104884 Start Date*: 2006-03-01
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: LPL104884: A multicenter, randomized, double-blind, placebocontrolled, parallel-group, dose-ranging study of SB-480848, an oral lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, in subje...
    Medical condition: SB-480848 is under developement as a potential anti-atherosclerosis agent for reduction of major cardiovascular events in high risk patient populations.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Completed) EE (Completed) HU (Completed) DE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2005-002942-20 Sponsor Protocol Number: EFC5826 Start Date*: 2005-12-29
    Sponsor Name:sanofi-aventis recherche et developpement
    Full Title: Randomized, multinational, multicenter, double-blind, placebo-controlled, two-arm parallel group trial of rimonabant 20 mg OD for reducing the risk of major cardiovascular events in abdominally obe...
    Medical condition: Patients with abdominal obesity at increased risk for cardiovascular events (myocardial infarctio, stroke and cardiovascular death)
    Disease: Version SOC Term Classification Code Term Level
    10.1 10051615 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prohibited by CA) GB (Prematurely Ended) ES (Completed) DE (Completed) AT (Prematurely Ended) FI (Completed) BE (Completed) DK (Suspended by CA) HU (Completed) CZ (Suspended by CA) IE (Prematurely Ended) PT (Completed) GR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-004877-38 Sponsor Protocol Number: PREVENT-MINS Start Date*: 2021-06-18
    Sponsor Name:Uniwersytet Jagielloński - Collegium Medicum
    Full Title: Ivabradine for PREVENTion of Myocardial Injury after Noncardiac Surgery (MINS) - PREVENT-MINS Trial
    Medical condition: Myocardial Injury after Noncardiac Surgery
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10028601 Myocardial ischemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-004016-12 Sponsor Protocol Number: Start Date*: 2009-01-21
    Sponsor Name:Lijf en Leven
    Full Title: Clopidogrel for the prevention of late cardiac events in patients with asymptomatic perioperative acute coronary syndrome.
    Medical condition: Study target patients are those with peripheral arterial disease who underwent a major vascular surgery and develop asymptomatic troponine-elevation. These patients are randomised for treatment wit...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10034638 Peripheral vascular disorders NEC HLT
    9.1 10018106 Generalized arterial disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-018173-31 Sponsor Protocol Number: POISE-2 Start Date*: 2011-02-25
    Sponsor Name:Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
    Full Title: Ensayo clínico factorial de clonidina y aspirina en pacientes que van a ser sometidos a cirugía no cardiaca y que estén en riesgo moderado o alto de sufrir eventos cardíacos perioperatorios (Estudi...
    Medical condition: Prevención de episodios cardiovasculares en pacientes de moderado a alto riesgo cardiovascular que son sometidos a una cirugía no cardiaca.
    Disease: Version SOC Term Classification Code Term Level
    9 10007649 Cardiovascular disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed) AT (Completed) BE (Completed) DK (Completed) GB (Completed) DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-003194-22 Sponsor Protocol Number: APHP200009 Start Date*: Information not available in EudraCT
    Sponsor Name:Assistance Publique – Hôpitaux de Paris (AP-HP)
    Full Title: A RANDOMIZED PHASE III MULTICENTER TRIAL COMPARING THE EFFICACY AND SAFETY OF ANAKINRA VERSUS INTRAVENOUS IMMUNOGLOBULIN (IVIG) RETREATMENT, IN PATIENTS WITH KAWASAKI DISEASE WHO FAILED TO RESPOND ...
    Medical condition: Anakinra treatment is expected to reduce the early and long-term mortality of patients with Kawasaki Disease (KD), by a rapid and sustained effect on vascular inflammation.
    Disease:
    Population Age: Infants and toddlers, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-005066-22 Sponsor Protocol Number: CTSU_MDCO-PCS-17-01 Start Date*: 2018-06-11
    Sponsor Name:University of Oxford [...]
    1. University of Oxford
    2. The Medicines Company
    Full Title: HPS-4/TIMI 65/ORION-4: A double-blind randomized placebo-controlled trial assessing the effects of inclisiran on clinical outcomes among people with atherosclerotic cardiovascular disease
    Medical condition: Atherosclerotic cardiovascular disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10051615 Atherosclerotic cardiovascular disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2007-004448-60 Sponsor Protocol Number: 0653A-128 Start Date*: 2007-11-13
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Parallel Arm, 12-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet Versus Atorvastatin in Elderly Patients With Hyp...
    Medical condition: Hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020604 Hypercholesterolemia LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: LT (Completed) IE (Completed) FI (Completed) BE (Completed) DK (Completed) DE (Completed) IT (Completed) AT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2013-002644-87 Sponsor Protocol Number: B1481021 Start Date*: 2013-11-27
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A 52 WEEK, PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED,PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF PF-04950615 IN SUBJECTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLE...
    Medical condition: Heterozygous Familial Hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004861 10020604 Hypercholesterolemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) GB (Completed) NL (Completed) NO (Completed) ES (Completed) IT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2020-004393-22 Sponsor Protocol Number: LIB003-006 Start Date*: 2022-01-13
    Sponsor Name:LIB Therapeutics, LLC
    Full Title: Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of LIB003 in Patients With Cardiovascular Disease, or at High Risk for Cardiovascular Disea...
    Medical condition: Patients With Cardiovascular Disease or at High Risk for Cardiovascular Disease, on Stable Lipid-Lowering Therapy Requiring Additional Low-Density Lipoprotein Cholesterol Reduction
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004849 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NO (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000478-20 Sponsor Protocol Number: B1481045 Start Date*: 2014-10-21
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, ny 10017
    Full Title: A 52 WEEK, PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBOCONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF PF-04950615 IN SUBJECTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED ...
    Medical condition: Primary Hyperlipidemia or mixed Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004861 10020667 Hyperlipidemia LLT
    17.1 100000004861 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) GB (Completed) SE (Completed) CZ (Completed) NL (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2008-005779-86 Sponsor Protocol Number: GFT505-208-3 Start Date*: 2008-12-26
    Sponsor Name:GENFIT
    Full Title: A Pilot study to evaluate the Efficacy and Safety of GFT505 (80 mg) orally administered once daily for 28 days in atherogenic dyslipidaemic patients with abdominal obesity. A double blind, placebo-...
    Medical condition: Atherogenic dyslipidaemic patients with abdominal obesity
    Disease: Version SOC Term Classification Code Term Level
    9.1 10058108 Dyslipidaemia LLT
    9.1 10059179 Abdominal obesity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 01:31:28 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA